Savient On Track To Resubmit Krystexxa BLA In Early 2010, Exec Maintains
This article was originally published in The Pink Sheet Daily
Executive Summary
After a Sept. 14 meeting with the FDA, the biotech is confident it can satisfy all points in a complete response letter - including the gout therapy's REMS.